872512-18-0

Basic information

• Product Name: 6-Chloro-N-(tetrahydro-2-furanylmethyl)-4-pyrimidinamine
• Synonyms: 6-Chloro-N-(tetrahydro-2-furanylmethyl)-4-pyrimidinamine;6-chloro-N-((tetrahydrofuran-2-yl)methyl)pyrimidin-4-amine
• CAS NO: 872512-18-0
• Molecular Formula: C₉H₁₂ClN₃O
• Molecular Weight: 213.66408
• Mol File: 872512-18-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Chloro-N-(tetrahydro-2-furanylmethyl)-4-pyrimidinamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-N-(tetrahydro-2-furanylmethyl)-4-pyrimidinamine(872512-18-0)
• EPA Substance Registry System: 6-Chloro-N-(tetrahydro-2-furanylmethyl)-4-pyrimidinamine(872512-18-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 872512-18-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-N-(tetrahydro-2-furanylmethyl)-4-pyrimidinamine is used as a precursor in the synthesis of diaminopyrimidine derivatives for their kinase inhibitory activity. This application is crucial in the development of drugs that can target and modulate the activity of specific kinases, which are enzymes involved in various cellular processes and are often implicated in diseases such as cancer and inflammatory conditions. By inhibiting these kinases, the diaminopyrimidine derivatives can potentially lead to therapeutic benefits in treating these diseases.

Upstream product

• 4795-29-3 TETRAHYDROFURFURYLAMINE 
• 1193-21-1 4,6-dichloropyrimidine 

Relevant articles and documents

Diaminopyrimidine derivatives for kinase inhibitors

The present invention relates to a novel diaminopyrimidine compound and a pharmaceutically acceptable salt thereof, a method for producing the compound, and a medical use of the compound as an anticancer agent. According to the present invention, the nove

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.